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Abstract
Background: The number of circulating tumor cells (CTCs) in metastatic prostate cancer patients provides
prognostic and predictive information. However, it is the molecular characterization of CTCs that offers insight into
the biology of these tumor cells in the context of personalized treatment.
Methods: We developed a novel approach to isolate CTCs away from hematopoietic cells with high purity,
enabling genomic analysis of these cells. The isolation protocol involves immunomagnetic enrichment followed by
fluorescence activated cell sorting (IE/FACS). To evaluate the feasibility of isolation of CTCs by IE/FACS and
downstream genomic profiling, we conducted a pilot study in patients with metastatic castration resistant prostate
cancer (CRPC). Twenty (20) sequential CRPC patients were assayed using CellSearch™. Twelve (12) patients positive
for CTCs were subjected to immunomagnetic enrichment and fluorescence activated cell sorting (IE/FACS) to
isolate CTCs. Genomic DNA of CTCs was subjected to whole genome amplification (WGA) followed by gene copy
number analysis via array comparative genomic hybridization (aCGH).
Results: CTCs from nine (9) patients successfully profiled were observed to have multiple copy number aberrations
including those previously reported in primary prostate tumors such as gains in 8q and losses in 8p. High-level copy
number gains at the androgen receptor (AR) locus were observed in 7 (78%) cases. Comparison of genomic profiles
between CTCs and archival primary tumors from the same patients revealed common lineage. However, high-level
copy number gains in the AR locus were observed in CTCs, but not in the matched archival primary tumors.
Conclusions: We developed a new approach to isolate prostate CTCs without significant leukocyte admixture, and
to subject them to genome-wide copy number analysis. Our assay may be utilized to explore genomic events
involved in cancer progression, e.g. development of castration resistance and to monitor therapeutic efficacy of
targeted therapies in clinical trials in a relatively non-invasive manner.
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Background
Cancer metastasis typically occurs through hematogen-
ous spread, and thus strategies to detect tumor cells in
the blood have been developed. Such detection methods
may be used in applications such as staging/prognosis,
disease monitoring, and studies of the metastatic process
[1-3]. For example, monitoring of CTC levels via immu-
nomagnetic enrichment and fluorescence based micro-
scopy (Cell Search™, Veridex LLC) has been shown to
be prognostic in metastatic breast cancer patients and
predictive of treatment response [4,5]. In metastatic
prostate cancer, de Bono et al [6] demonstrated that
CTC levels as enumerated by this approach predicted
overall survival better than PSA decrement algorithms
in the CRPC patient population. The presence of ≥ 5
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CTCs per 7.5 mL of blood at any time point was signifi-
cantly associated with poor prognosis.
The biological significance of CTCs remains unknown,
underscoring the need for functional analysis and mole-
cular characterization of these cells. Furthermore, the
role of CTC detection in the clinical management of
prostate cancer remains debated. For example, the rela-
tion of CTCs to currently used diagnostic tools, such as
clinical nomograms, is unclear. Therefore, it is of inter-
est to develop approaches to further characterize these
cells. Detailed molecular characterization of CTCs, how-
ever, has been hampered because of their rarity and the
difficulty of isolating CTCs for analytical techniques [for
review see Ref. [3]].
Here we describe a new approach for prostate CTC
isolation and genomic profiling, using immunomagnetic
enrichment (IE) and fluorescence activated cell sorting
(FACS) to purify CTCs, and array comparative genomic
hybridization (aCGH) to evaluate copy number aberra-
tions. We evaluated our assay in a pilot study involving
patients with CRPC who had received chemotherapy.
Using this protocol, CTCs were isolated and profiled for
copy number aberrations via aCGH analysis following
whole genome amplification (WGA). Results of copy
number analysis confirmed their malignant nature and
revealed aberrations commonly seen in primary prostate
cancer. Additionally, our results suggested that CTCs
isolated via IE/FACS were highly pure without signifi-
cant dilution by hematopoietic cells.
Methods
Patient samples
Clinical samples were obtained from 20 castration resis-
tant prostate cancer patients who were recruited from
November 2008 to August 2009 at the University of
California San Francisco (UCSF) to participate in our
study (Table 1). Twenty patients were selected based on
statistical considerations for a pilot study. All patients
gave informed consent under a protocol approved by
the UCSF Institutional Review Board. Blood was col-
lected in three CellSave™ tubes (Veridex). This allowed
us to use one tube for an initial CTC enumeration using
the published CellSearch™ method, and the two
remaining tubes to be combined for IE/FACS isolation.
Microdissection and DNA extraction of archived forma-
lin-fixed paraffin-embedded (FFPE) tumor biopsy sam-
ples from two patients were done in a manner as
previously described [7]. Using H&E stained slide, the
pathologist (J.S.) demarcated tissue containing at least
80% tumor. The H&E stained slide was then used as a
guide to microdissect the tumor area using a surgical
blade (Feather #15) on non-stained deparaffinized sec-
tions (10 sections × 5 μM thickness). In the case of a
small tumor (Patient #20), manual microdissection of
the selected area was performed by scraping successive
tissue sections under a stereomicroscope.
Patient eligibility criteria
This pilot study was conducted among men with pros-
tate cancer who met the following criteria: histologi-
cally-proven castration resistant prostate cancer that has
metastasized; prior therapy with ≥ 3 cycles (9 weeks) of
docetaxel based chemotherapy; progressive disease
within the last 1-2 months as characterized by rising
PSA level, new lesions on radionuclide bone scan or
computed tomography scans; last dose of docetaxel ≥ 21
days prior to blood collection; no chemotherapy within
the previous 21 days and no radiation therapy within 21
days.
Enumeration of CTCs
To increase the likelihood of isolating CTCs for molecu-
lar analysis, we first performed CTC enumeration using
the automated CellSearch™ assay to identify patients
with > 5 CTCs per 7.5 mL. We then isolated CTCs by
IE/FACS (see below) from the remaining blood sample
in these patients. Cell counts via CellSearch™ correlated
closely with cell counts via IE/FACS (Park, unpublished
data). In initial studies, we observed that whole genome
amplification of DNA from CTCs was less efficient
when CTCs were isolated after 48 h post-phlebotomy.
Therefore, enumeration was performed within 24 h and
isolation of CTCs via IE/FACS within 48 h after blood
draw.
Cell isolation via IE/FACS
For immunomagnetic enrichment, one-half volume of
Cell Buffer (Immunicon) was added to a blood sample.
Immunomagnetic particles coated with EpCAM (MJ37)
mAb (50 μg/10 mL of indirect conjugate or 60 μg/10
mL for the direct conjugate) and EpCAM (EBA-1) mAb
conjugated to phycoerythrin (PE) (400 μL at 5 μg/mL
per 10 mL of sample) were added to the sample. The
sample was incubated at room temperature for 15 min,
mixing at half-way point and again when incubation was
completed. The sample was placed in a magnetic
separator (Immunicon) at room temp for 15 min, and
then aspirated to remove unbound blood cells. The
bound cells were eluted in 2 mL of Cell Buffer, moved
to a 12 × 75 mm tube and subjected to a second round
of magnetic separation for 5 min. The fluid in the tube
was aspirated and the remaining cells were resuspended
in 150 μL of Cell Buffer. Twenty μL of a solution con-
taining 2 μg of a proprietary (BD Bioscience) nucleic
acid dye, and 0.1 μg of a leukocyte-specific CD45 (2D1)
mAb conjugated to peridinin-chlorophyll-protein-Cy5.5
were added to resuspended cells. The sample was incu-
bated in the dark for 15 min and then sorted using
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FACS Aria (BD Biosciences). CTCs were defined as
nucleated, EpCAM-positive, and CD45-negative while
leukocytes were defined as CD45-positive, EpCAM-
negative and nucleated. Cells were sorted into 10 μL of
TE (10 mM Tris-HCl 1 mM EDTA pH 8.0) in a 500 μL
PCR tube. All conjugated antibodies and reagents for
FACS were obtained from BD Biosciences unless other-
wise noted. During FACS analysis, we sorted a range of
18-50 CTCs. Table 1 shows the number of “input cells”
used for WGA, and the number of replicate analyses
performed for each subject. Due to the small numbers
of CTCs isolated from patients’ blood, it was not feasible
to perform FACS analysis after sorting. Also, since blood
samples were collected in CellSave™ (Veridex) tubes
[6,8], CTCs were thereby rendered nonviable and fixed
to maintain antigenicity prior to immunomagnetic
enrichment and FACS sorting. Complete FACS plots
from two representative patients are shown in Addi-
tional file 1: Figure S1.
Optimization of whole genome amplification (WGA)
ACGH protocols typically use between 100 ng and 1 μg
of specimen DNA in the labeling reaction, equivalent to
~20,000-200,000 cells, which does not permit reliable
analysis of important samples containing small numbers
of tumor cells such as CTCs in blood. Analyzing these
samples for copy number aberration requires a high-
fidelity whole genome amplification (WGA) step. To
select the best strategy for WGA of limiting amounts of
input DNA, we tested four WGA protocols: multiple
displacement amplification [9], random prime amplifica-
tion [10], ligation-mediated-PCR [11], and the Genome-
Plex® WGA4 [12,13]. We compared aCGH results
generated from diluted BT474 breast cancer cell line
genomic DNA (equivalent to ~10,000 to 10 cells) to
non-limiting unamplifed BT474 DNA (600 ng). We
found GenomePlex® WGA4 to be most reliable and
reproducible (data not shown). We also did not observe
artifacts or bias via BAC aCGH analysis. Other groups
have also demonstrated the reproducibility and reliabil-
ity of the GenomePlex® WGA protocol [12,14].
Whole genome amplification (WGA)
To prevent any loss of genomic material, we avoided the
use of column purification of genomic DNA. Instead,
whole cell lysis of isolated cells and WGA of genomic
DNA were performed in the same PCR tube the cells
were sorted into. Genomic DNA in the whole cell lysate






IE/FACS Days from draw to IE/
FACS
No. of cells collected as input for
WGA
aCGH
1 1 n.d. N.A. N.A. N.A.
2 1 n.d. N.A. N.A. N.A.
3 85 Yes 1 50 Yes
4 12 Insufficient sample N.A. N.A. N.A.
5 144 Failed due to machine
error
1 N.A. N.A.
6 6 Insufficient sample N.A. N.A. N.A.
7 10 Insufficient sample N.A. N.A. N.A.
8 2 n.d. N.A. N.A. N.A.
9 590 Yes 1 20 × 2 Yes (duplicate)
10 151 Yes 4 20 Yes
11 9 Yes 2 20 Yes
12 2 n.d. N.A. N.A. N.A.
13 55 Yes 1 20 Yes
14 590 Yes 2 20 Yes
15 42 Yes 2 33 WGA failed
16 0 n.d. N.A. N.A. N.A.
17* 54 Yes 1 20 Yes
18 33 Yes 1 20 Yes
19 34 Yes 2 20 Hybridization
failed
20* 12 Yes 1 18 Yes
*Patients with available matched primary tumor
IE/FACS-immunomagnetic enrichment and fluorescence activated cell sorting; aCGH-array comparative genomic hybridization; WGA-whole genome amplification;
n.d.-not done; N.A.-not applicable
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served as template for WGA which was performed using
the GenomePlex® Single Cell WGA4 Kit (Sigma-
Aldrich) following the manufacturer’s protocol. Briefly, 1
μL lysis and proteinase K digestion solution was added
to cells in 10 μL of TE. The DNA was then fragmented
and libraries were prepared. Amplification was per-
formed by adding 7.5 μL of 10 × Amplification Master
Mix, 48.5 μL of nuclease-free water and 5 μL WGA
DNA polymerase. Samples were amplified using an
initial denaturation of 95°C for 3 min followed by 25
cycles, each consisting of a denaturation step at 94°C for
30s and an annealing/extension step at 65°C for 5 min.
Amplified DNA was purified using the QIAQuick PCR
Purification Kit (Qiagen). DNA concentration was deter-
mined by a NanoDrop™ spectrophotometer and stored
at -20°C. The average yield after WGA of ~20 CTCs is
~10 μg. Early tests via aCGH analysis of samples with
WGA product yield less than < 5 μg revealed non-speci-
fic amplification. Therefore samples with low yield (< 5
μg) were excluded from further downstream assays.
Array CGH analysis
In initial studies we performed aCGH analysis using oli-
gonucleotide microarrays (Affymetrix 50 K SNP array),
but observed significant experimental variability and
background noise with our WGA4 amplified DNA sam-
ples. Similarly, studies by Fuhrmann et al [15] and
Nowak et al [14] showed that bacterial artificial chromo-
some (BAC) arrays outperformed oligonucleotide micro-
arrays in detecting small gains or losses [15] and
showed far fewer outliers and less technical noise [14].
So, we performed our aCGH analysis using a bacterial
artificial chromosome (BAC) array (Version 3.2) con-
taining 2,464 clones printed in triplicate [16]. The BAC
arrays are available at the Helen Diller Family Compre-
hensive Cancer Center Array Core.
The random prime amplification method [16] was
used to enzymatically label approximately 600 ng of test
DNA (WGA product) or unamplified normal female
genomic (Promega) reference DNA with Cyanine 3-
dCTP or Cyanine 5-dCTP (Amersham), respectively.
Labeled test and reference DNA were co-hybridized to a
BAC array. The arrays were imaged using a custom
built CCD array imaging system [17] and analyzed using
the UCSF Spot Program to calculate Cy3/Cy5 ratios.
The UCSF Spot Program is a fully automated system for
microarray imaging that locates both subarray grids and
individual spots [18]. Ratios are then computed based
on explicit segmentation of each spot. The resultant
log2 ratios were analyzed by UCSF Sproc to yield the
mean and standard deviation of the log2 ratios over
replicate spots. The UCSF Sproc is a companion pro-
gram to UCSF Spot that maps each spot on the array to
a specific clone and chromosome position, and averages
over replicate spots in order to output a final ratio value
for each clone on the array. Clones with a standard
deviation of the log2 ratios of the triplicate spots greater
than 0.2 for were excluded from analysis.
To determine copy number alterations, microarray
data (sproc files) was uploaded and analyzed using
Nexus 5.1 software (Biodiscovery). Data was subjected
to rank segmentation, a proprietary (Biodiscovery) varia-
tion of the circular binary segmentation (CBS) [19]. The
thresholds of log2 ratio values for gains and losses were
0.2 and -0.2 respectively; the thresholds for high copy
number gains and homozygous deletions were 0.6 and
-0.6 respectively. Copy number gains or losses were con-
sidered recurrent if present in > 50% of the CTC sam-
ples from 9 patients.
Since sex-mismatch hybridization was performed, i.e.
male test (tumor) versus female (normal) reference, we
analyzed copy number alterations on chromosome X by
using a feature available in the Nexus 5.1 software for
automatic threshold adjustment on the X chromosome.
Theoretically, the intensity of a normal male test sample
on the X chromosome is 1/2 that of the normal female
reference (i.e. 1 versus 2 copies of chromosome X). If
the same threshold used for autosomal chromosomes
was applied on X, the segmentation result will show
“one copy number loss” But when corrected for gender,
the segmentation analysis will no longer pick up the
“copy number loss on X” because the adjusted threshold
takes into account that the male sample will have 1/2
the intensity on the X chromosome compared to that of
the female reference. Therefore, the automatic threshold
adjustment feature allows the segmentation analysis to
take into account the sex-mismatch hybridization so
only copy number changes on the X chromosome that
deviated from the expected normal ratio was reported.
Chromosome Y was excluded in the analysis.
Concordance between aCGH profiles was measured
using weighted Pearson correlation. A weighted Pearson
measure was used because, in aCGH comparisons,
unweighted Pearson correlation is driven by the number
of ratios that differ from “normal.” Since the observa-
tions in this case are the clones, one can use the spatial
relationship of the clones to estimate the weights. Based
on this idea, the weight of a clone was estimated by
considering its deviation and that of its adjacent clone
from “normal” The formula used for calculating
weighted correlation coefficient (corr) is given below:
rw =
cov (x, y;w)
cov (x, x,w)cov (y, y;w)
,
where x and y are the log2 ratio values of the two




(median(|xj − xref |) +median(|yj − yref |)) ; i =
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1,2,...,n-1; j = i, i + 1; n = total number of clones; and
xref and yref are the medians of the n clones for samples
x and y, respectively. Only autosomal clones were con-
sidered. Correlation coefficients falling in the intervals 0
to < 0.20, 0.20 to < 0.40, 0.40 to < 0.60, 0.60 to < 0.80
and 0.80 to 1 were said to be un-, lowly-, fairly-, moder-
ately- and highly- correlated, respectively.
Results
Methods development
For proof of principle studies using a spiked tumor cell
model system, we chose LNCaP, PC3, and VCaP cell
lines because they have well-characterized copy number
aberrations [20]. Of note, initial tests on diluted geno-
mic DNA and isolated spiked cells using breast cancer
cell line BT474 showed that the optimal input for WGA
which yielded robust aCGH results was ~20 cells (data
not shown). For each prostate cell line, 1000 trypsinized
cells were spiked into 10 mL of whole blood from
healthy volunteers. Twenty (20) tumor cells were col-
lected in duplicate via IE/FACS. Isolated cells were then
subjected to WGA and aCGH analysis. The resulting
genomic profiles demonstrated the expected known
copy number aberrations (Figure 1A-C), as did aCGH
profiles from amplified genomic DNA (50 ng) and non-
amplified genomic DNA (600 ng) performed as a posi-
tive control. Profiles derived from 20 tumor cell-inputs
revealed moderate to high correlation with the positive
control (Table 2) indicating minimal dilution from con-
taminating normal leukocyte DNA, which would have
otherwise dampened dynamic range [21]. Furthermore,
consistent with previous genomic studies on VCaP cells
[20], a focal amplification in the X-chromosome region
containing AR was observed (Figure 1C).
Enumeration, isolation and aCGH analysis of CTCs
Twenty (20) sequential CRPC patients were assayed for
CTC level by CellSearch™ (see Additional file 2: Figure
S2 for study schema). Fifteen (15) patients showed ≥ 5
CTCs per 7.5 mL, the cutoff used in prior clinical trials
of this assay in metastatic prostate cancer [6], with
mean = 12.2 and median = 3.0 CTC/mL (Table 1). Of
these 15 patients who were positive for CTCs, twelve
(12) were subjected to CTC isolation via IE/FACS.
Three patients were excluded from further analysis
because of insufficient amount of remaining blood. Nine
(9) were successfully analyzed for copy number aberra-
tions. Three of the 12 samples that met the established
parameters to move forward with IE/FACS did not yield
informative aCGH results (25% failure rate) due to
FACS instrument error, inadequate WGA yield, or failed
microarray hybridization. Two of the samples (patients
#15 and #19) were processed 2 days after blood draw
(Table 1). Based on this observation, we suggest imple-
menting IE/FACS within 24 h after blood draw.
Isolated CTCs from these CRPC patients exhibited
copy number aberrations indicative of malignant origin.
Due to the paucity of FACS sorted CTCs, re-analysis by
FACS to confirm purity and the correct expression of
biomarkers was not performed; hence, the isolation of
falsely positive “EpCAM+/CD45-” cells cannot be ruled
out. However, the resulting aCGH profiles showed
unequivocal evidence of cancer-associated genomic
alterations, and did not appear to be significantly dam-
pened by false positive normal cells. For example, copy
number analysis of replicate CTC isolates from patient
#9 revealed gains including focal amplification in 11q13
(includes CCND1) and high-level gains in a region on
chromosome X including the AR locus (Figure 2A).
Also, replicates were moderately correlated (r = 0.78)
indicating the reproducibility of the assay. As expected,
these copy number aberrations were not observed in
100 leukocytes isolated from the same enriched sample
(Figure 2B, Additional file 3: Figure S3C).
ACGH analysis of CTCs from all 9 patients revealed a
wide range of copy number aberrations, including those
that have been previously reported in prostate tumors
([22,23] Figure 3 and Additional file 3: Figure S3). Copy
number aberrations present in > 50% of the samples
include gains at 1q, 4q, 7q, 8q, 9p, 9q, 11q, 19q, Xp, and
Xq and losses in 1p, 4q, 5q, 8p, 10q, 11q, 13q, 14q, 15q,
and 16q (Additional file 4: Table S1). Of note, high-level
gains in the region of chromosome X containing the AR
locus were observed in 7 (78%) of the 9 cases, while low
level copy number gains were observed in the remaining
2 (22%) cases (Figure 4). These results suggest that
CTCs may reveal evidence for AR amplification, which
has been associated with disease progression in CRPC
[24].
CTCs versus matched archival primary tumors
In patients #17 and #20, archival tissue previously
obtained at time of primary tumor diagnosis, and prior
to any cancer therapy, was available. These tumor speci-
mens were subjected aCGH analysis and compared to
the corresponding CTC samples.
Patient #17 is a 48-year old CRPC patient initially
diagnosed with prostatic adenocarcinoma with Gleason
score 9 (4 + 5), and with local extension to the urinary
bladder. The aCGH analysis of his CTCs revealed geno-
mic aberrations including high-level gains at 18p, 19q
and the AR locus of chromosome X; and losses at 8p
and 18q (Figure 5A, Additional file 3: Figure S3H). The
archival primary tumor specimen involving the bladder
from this same patient, which dated to 1 year and 3
months prior to CTC analysis, was obtained for aCGH
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analysis as well. Only tumor from the bladder yielded
informative aCGH profile (Additional file 3: Figure S3I).
Comparison of the respective genomic profiles revealed
shared copy number aberrations indicative of common
lineage, including losses in 8p and 18q as well as gains
in 8q, 18p and 19q (Additional file 3: Figure S3A).
Conversely, new copy number aberrations were
observed in CTCs but not in the primary tumor, includ-
ing copy number gain at the AR locus (Figure 4).
Patient #20 is a 67-year old CRPC patient initially
diagnosed with prostatic adenocarcinoma with Gleason
score 8 (4 + 4). ACGH analysis of his CTCs revealed
LNCaP genomic DNA amplified (50ng)





PC3 genomic DNA amplified (50ng)
PC3 genomic DNA unamplified (600ng)
20 VCaP cells
20 VCaP cells
VCaP genomic DNA amplified (50ng)
VCaP genomic DNA unamplified (600ng)
a b c
Figure 1 Copy number analysis of spiked cells isolated from healthy blood via IE/FACS. Twenty (20) isolated (A) LNCaP, (B) PC3 and (C)
VCaP cells (in duplicate) and 50 ng of genomic DNA from cell culture subjected to whole genome amplification, and unamplified genomic DNA
(600 ng) from cell culture (positive control) were analyzed for copy number aberrations. The log2 ratio value for each BAC clone is plotted on
the y-axis. The x-axis represents the genomic position of each BAC clone on the array, with chromosome numbers indicated. Vertical solid lines
indicate chromosome boundaries, and vertical red dashed line represents the centromeric region dividing each chromosome into the p- or
short arm (to the left of centromere) and the q- or long arm (to the right of the centromere). Arrows indicate high-level gains on X
chromosome region containing AR observed in VCaP cells.
Table 2 Correlation analysis of genomic profiles of spiked cells isolated from blood via IE/FACS.
Cell Line Source Input for WGA No. of replicates Correlation with positive control S.D.
LNCaP IE/FACS 20 cells 2 0.63 0.15
Cell culture 50 ng 1 0.82 n.a.
PC3 IE/FACS 20 cells 2 0.88 0.03
Cell culture 50 ng 1 0.97 n.a.
VCaP IE/FACS 20 cells 2 0.82 0.02
Cell culture 50 ng 1 0.89 n.a.
Isolated 20 tumor cells (in duplicate) and genomic DNA (50 ng) from cell culture were subjected to WGA and aCGH analysis and compared to positive control:
unamplified genomic DNA (600 ng) from cell culture
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genomic aberrations including high-level gains in 8q and
in a region on chromosome X containing AR, as well as
loss of 13q (Figure 5B; Additional file 3: Figure S3K).
ACGH analysis of the corresponding primary tumor
(Additional file 3: Figure S3L) obtained via core biopsy 5







Figure 2 Copy number analysis of CTCs. Array comparative genomic hybridization analysis of (A) 20 CTCs in duplicate (B) and 100 leukocytes
(CD45-positive) isolated from the same enriched blood sample from patient #9. The log2 ratio value for each BAC clone is plotted on the y-axis.
The x-axis represents the genomic position of each BAC clone on the array, with chromosome numbers indicated. Vertical solid lines indicate
chromosome boundaries, and vertical red dashed line represents the centromeric region dividing each chromosome into the p- or short arm (to
the left of centromere) and the q- or long arm (to the right of the centromere). Arrows indicate high-level gains on X chromosome region
containing AR.
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similarities in copy number alterations when compared
with the CTCs, including losses in 8p, 10q, and 11p and
gains in 8q and 9q (Additional file 5: Figure S4B). In
addition to these conserved genomic aberrations, new
copy number changes were evident, particularly the AR
region gain shown in CTCs but not in the primary
tumor (Figure 4).
Discussion
In this pilot study, we assessed the feasibility of a new
approach to isolate and genomically profile CTCs in
patients with CRPC. Molecular profiling of CTCs
revealed genomic aberrations that have been previously
described in prostate cancer including gains in 8q,
11q13 and losses in 8p [22,23].
Our approach involving immunomagnetic enrichment,
FACS sorting and aCGH analysis is novel, and this
report confirms the feasibility of this approach for geno-
mic analysis of isolated CTCs. Immunomagnetic enrich-
ment alone provides a cell mixture which is
predominantly hematopoietic, although further analysis
may be performed on the admixture of cells [25-27]. In
a notable prior report, Racila et al. described immuno-
magnetic enrichment followed by flow cytometry for
enumeration of CTCs, as well as enrichment followed
by cytospin for immunostaining [28]. Our approach
enables full FACS-based isolation of CTCs for molecular
profiling.
Interestingly, we observed copy number gains in the
AR region of chromosome X of CTCs, including high-
level gains in 78% of the samples which were success-
fully profiled. AR amplification is not a common event
in primary prostate cancer, but has been implicated in
hormone resistance in CRPC [24,29]. In the two patients
with matching archival tumor and subsequent CTC spe-
cimens, high-level gain in the AR region was observed
in the CRPC CTCs but not in the archival tumors. The
gain in AR copy number between tumor tissue obtained
at initial diagnosis and CTCs subsequently obtained
during the CRPC phase may reflect selective pressures
towards amplification of the AR in response to andro-
gen deprivation therapy. Although our approach for
whole genome amplification and aCGH of isolated
CTCs is not designed to be a clinical test, it is possible
that the observations here, such as focal amplification in
the X chromosome (AR) in CTCs, could serve as the
basis for new CTC-based clinical applications. Finally,
we performed manual microdissection of archival sam-
ples, which can potentially include adjacent benign tis-
sue. Moreover, since prostate cancer is multifocal [30],
the use of laser microdissection to isolate different
clones present in the primary tumor will further refine
our understanding of the clonal relationships of CTCs
and their primary tumor focus of origin.
A major limitation of this study is that it was designed
as a pilot feasibility study with a small sample size.
Another potential limitation of this approach is that it
was only focused on EpCAM-positive CTCs. EpCAM-
based selection methods, such as IE/FACS and Cell-
Search™, may miss CTCs expressing low levels of
EpCAM. The clinical significance of EpCAM-negative
CTCs has yet to be determined, but it has been
hypothesized that this may include cells undergoing
epithelial-mesenchymal transition [31].
Molecular studies using specific FISH probes on CTCs
from advanced prostate cancer patients have noted gains
in AR and MYC, losses in PTEN, and evidence for ERG
gene rearrangement [32,33]. In addition, Stott et al [34]
also reported TMPRSS2-ERG fusion in CTCs via RT-
PCR. Genome-wide copy number microarray analysis
has been performed on disseminated tumor cells
(DTCs) obtained from bone marrow aspirates performed
on prostate cancer patients [35,36]. Such efforts have
been facilitated by the higher numbers of tumor cells in
the bone marrow compared to blood [37]. For example,
Holcomb et al [35] demonstrated the feasibility of
aCGH analysis of pools of 10-20 DTCs from patients
with organ-confined and metastatic disease and found
Figure 3 Frequency of copy number alterations in CTCs from 9 metastatic CRPC patients. Gains and losses are shown in green and red,
respectively. Chromosome Y was not included in the analysis.
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more aberrations in DTCs in the latter. They also
showed shared genomic aberrations between DTCs and
their matched primary tumors. Recently, Paris and col-
leagues [38] reported on copy number analysis of CTCs
from CRPC patients obtained via a cell adherence based
enrichment method.
Conclusions
In summary, our pilot study demonstrates that CTCs
can be feasibly isolated away from hematopoietic cells
via IE/FACS and profiled for genome-wide copy number
aberrations. The resulting copy number analyses provide













Figure 4 X chromosome and AR locus copy number analysis in CTCs from 9 metastatic CRPC patients. Each plot shows log2
hybridization ratio values (y-axis) at BAC clones (blue dots) distributed from the p terminus to the q terminus (x-axis). The black horizontal lines
represent log2 ratio equal to 0. Red vertical lines demarcate the centromere. Broken black lines superimposed on BAC clones are the output of
segmentation analysis providing high confidence copy number calls. Transparent blue bars identify the locus containing the androgen receptor
gene (AR). At the bottom of each panel is an ideogram of chromosome X with cytoband regions showing gains (green) and losses (red). Bars on
top of the ideogram (long arm) show results of copy number analysis at the AR locus (double green bar- high-level copy number gain; single
green bar- low level copy number gain, grey bar- no copy number change). Paired samples are enclosed in black boxes: CTCs vs. CD45-positive
(leukocytes) from patient #9 and CTCs vs. archival primary tumor (PT) from patients #17 and #20.
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Figure 5 Copy number analysis of CTCs versus matched archival tumor in two patients. Array CGH analysis of (A) 20 CTCs from patient
#17 and a corresponding archival primary tumor from local extension to the bladder obtained 1 year and 3 months prior to CTC analysis; and
(B) 18 CTCs from patient #20 and a matched primary tumor obtained 5 years and 1 month prior to CTC analysis. Arrows indicate high-level gains
on X chromosome region containing AR in CTCs but not observed in archival primary tumors. Chromosome regions in red boxes show genomic
aberrations common to both paired samples (Also see Additional file 3: Figure S3).
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positive cells in the blood. Most importantly, this
approach may be used to explore genomic events asso-
ciated with cancer progression, and may facilitate CTC-
based biomarker discovery.
Additional material
Additional file 1: Figure S1 Fluorescence activated cell sorting
(FACS) analysis of two representative clinical blood samples
positive for CTCs. Samples after immunomagnetic enrichment (enriched
for tumor cells) were subjected to fluorescence activated cells sorting
(FACS) to isolate for CTCs. Tumor cells were stained with EpCAM (EBA-1)
mAb conjugated to phycoerythrin (EpCAM-PE), a nucleic acid dye and a
leukocyte-specific CD45 (2D1) mAb conjugated to peridinin-chlorophyll-
protein-Cy5.5 (CD45-PerCPCy5.5). Forward and side scatters (top left
panel) were used for preliminary identification of cells (P1 gate) and to
exclude debris. P2 gate (top right panel) was used to select for nucleated
(a nucleic acid dye+) cells while gates in the lower panels were used to
select for EpCAM + and CD45- (P3 gate) and EpCAM + and nucleated (a
nucleic acid dye+) cells (P4 gate). CTCs must be present within gates P1
to P4, and were defined as EpCAM+, CD45-, and nucleated (a nucleic
acid dye+). P5 gate (lower left panel) was used to select for CD45+,
EpCAM-, and nucleated (a nucleic acid dye+) cells when sorting for
leukocytes. Forward scatter (FSC) vs side scatter (SSC) plots are on a
linear scale while SSC vs nucleic acid dye plots are on a semi-logarithmic
scale. EpCAM-PE vs CD45-PerCP-Cy5.5 and EpCAM-PE vs nucleic acid dye
are log-log plots.
Additional file 2: Figure S2 Study schema. Flow diagram for
enumeration, immunomagnetic enrichment and fluorescence activated
cell sorting (IE/FACS), whole genome amplification (WGA) and array
comparative genomic hybridization (aCGH) analysis of circulating tumor
cells (CTCs) in castration resistant prostate cancer.
Additional file 3: Figure S3 (A-L). Copy number analysis of CTCs (N
= 9), archival primary tumor (N = 2) and leukocytes (N = 1). For
each case, the top panel shows genomic profiles and the lower panel
(karyograms) shows results from segmentation analysis providing high
confidence copy number calls in each sample: low level gains (green
bar) and losses (red bar), high-level gains (double green bars) and
homozygous deletion (double red bars).
Additional file 4: Table S1 Recurrent aberrations (> 50%) in
circulating tumor cells isolated from 9 castration resistant prostate
cancer patients. Genes and microRNA are listed for each region.
Additional file 5: Figure S4 Copy number analysis of CTCs versus
matched archival primary tumor in two patients. (A) 20 CTCs from
patient #17 and a corresponding archival primary tumor from local
extension to the bladder obtained 1 year and 3 months prior to CTC
analysis; and (B) 18 CTCs from patient #20 and a matched primary tumor
obtained 5 years and 1 month prior to CTC analysis. For each case, the
top panel shows frequency of genomic aberrations [gains (green) and
losses (red)] between the paired samples such that chromosomal
aberrations with frequency equal to 100% have been gained and lost in
both CTCs and archival primary tumor. The lower panel shows output of
segmentation analysis providing high confidence copy number calls for
each sample.
Abbreviations
aCGH: array comparative genomic hybridization; AR: androgen receptor;
CRPC: castration resistant prostate cancer; CTCs: circulating tumor cells; IE/
FACS: immunomagnetic enrichment/fluorescence activated cell sorting; PT:
primary tumor; WGA: whole genome amplification.
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